《藍籌業績》國藥(01099.HK)去年純利90.5億人幣升6.2% 派末期息87分人幣
國藥控股(01099.HK)公佈截至去年12月底止全年業績,營業額5,965.7億元人民幣(下同),按年升8%。純利90.54億元,按年升6.2%;每股盈利2.9元。派每股末期息87分,上年同期派82分。
期內,集團毛利率按年跌0.46個百分點,至8.13%。醫藥分銷業務收入4,410.51億元,按年增長8.47%;器械分銷業務收入升7.75%至1,302.13億元;醫藥零售板塊收入升8.22%至356.89億元。
截止去年底,集團醫藥分銷板塊收入佔比按年上升0.19個百分點,達71.44%;器械分銷板塊收入佔比按年微降0.09個百分點,達21.09%;醫藥零售板塊收入佔比較同期保持不變,爲5.78%。
此外,截至去年底集團零售藥房店鋪總數爲12,109家,按年淨增1,356家。其中國大藥房10,516家,按年淨增1,203家。專業藥房1,593家,按年淨增153家,已經覆蓋全國30個省、市、自治區,305個地級行政區。
集團展望,短期來看醫療行業恢復仍需克服疫情形成的衝擊和應對醫保改革帶來的傳統業務營利水平下降的挑戰,同時更面臨結構性轉型和發展新質生產力等全新的局面和要求。所以集團將在夯實主責主業的基礎上,進一步優化資源匹配,加速佈局戰略性新興產業,促進上下遊產業鏈延伸。通過構建新的核心競爭力,推動業態結構多元化發展,以自身的穩健發展應對外部環境不確定性的風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.